Vir Biotech partners with WuXi on COVID-19 antibody treatment

Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Webinar: antibody patents in Europe and beyond

6 August 2020 Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.

Americas

BIO moves 2020 international convention online

6 April 2020 The Biotechnology Innovation Organization has converted its 2020 international convention into an entirely online experience, BIO Digital.

Asia

GSK and Chinese biotech unite for coronavirus vaccine development

25 February 2020 British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Vir Biotech partners with WuXi on COVID-19 antibody treatment

More on this story

Editor's picks

Editor's picks

More features